ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1967

Sex Differences in Employment Outcomes in Patients with Recent Onset Rheumatoid Arthritis

Carol Hitchon1, Marie-France Valois2, orit schieir2, Louis Bessette3, Gilles Boire4, Susan Bartlett5, Glen Hazlewood6, Edward Keystone7, Janet Pope8, Carter Thorne9, Diane Tin10 and Vivian Bykerk11, 1University of Manitoba, Winnipeg, MB, Canada, 2McGill University, Montréal, QC, Canada, 3Centre de l'Ostoporose et de Rhumatologie de Québec, Québec, QC, Canada, 4Universite de Sherbrooke, Sherbrooke, QC, Canada, 5McGill University, Montreal, QC, Canada, 6University of Calgary, Calgary, AB, Canada, 7Keystone Consulting Enterprises Inc., Toronto, ON, Canada, 8University of Western Ontario, London, ON, Canada, 9Southlake Regional Health Centre, Newmarket, ON, Canada, 10The Arthritis Program Research Group, Newmarket, ON, Canada, 11Hospital for Special Surgery, New York, NY

Meeting: ACR Convergence 2022

Keywords: Cohort Study, Employment, rheumatoid arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 14, 2022

Title: RA – Diagnosis, Manifestations, and Outcomes Poster IV

Session Type: Poster Session D

Session Time: 1:00PM-3:00PM

Background/Purpose: Early work cessation and reduced work and activity productivity are significant contributors to the personal and societal costs associated with rheumatoid arthritis (RA). We sought to describe sex differences in work status and work productivity over time in newly diagnosed RA patients and to identify factors associated with work cessation.

Methods: Data were from early RA patients (< 1 year of symptoms at baseline), followed by rheumatologists across Canada and treated with disease modifying anti-rheumatic drug therapies (DMARDs) according to Treat-2-Target guidelines. Between November 2011 to March 2020, 945 participants reported work status (employed or not-employed), reasons for stopping work (RA, retirement, other) and work productivity as assessed by the Work Productivity and Activity Index (WPAI) annually over the first five years of follow-up. WPAI scores for overall work productivity loss with subscores for absenteeism (time away from work) and presenteeism (reduced productivity at work) and reduced general activity are expressed as impairment percentages (%) with higher numbers indicating greater impairment and less productivity. We used GEE regression models to estimate associations of sociodemographic and disease related variables with stopping work due to RA or early retirement (defined as retiring prior to age 65, the average retirement age in Canada). The analysis was stratified by sex. Odds ratio (OR) and 95% confidence intervals are reported.

Results: At baseline 479 (51%) were employed (131/278 males; 348/667 females). Of those not working at baseline, 2% had stopped working due to RA, 62% were retired and 36% had stopped working for other reasons. At baseline, participants reported mean 39.2% (29.6) overall work impairment, mean 8.5% (19.1) absenteeism, and mean 36.5% (27.9) presenteeism. WPAI scores improved during followup and were similar for males and females (Figure). Of those employed at baseline, 14% (47 women, 20 men) stopped working due to RA or retired early during the first 5 years of follow-up. Only 12 (29%) of those who stopped working due to RA returned to work (8/17 males 47%; 4/24 females 17%). Factors associated with stopping work due to RA or retiring early were for females age (OR 1.31; 1.16, 1.45), whereas previous visit pain (OR 0.9; 0.82, 0.99), oral steroid use (OR 0.38; 0.15, 0.92) and worse mental health RAND-12 mental health t-score increase of 5 (OR 0.87; 0.77, 0.97) reduced work stoppage. For males, stopping work was associated with previous visit pain (OR 1.31; 1.01,1.70) whereas increased household size of one other (OR 0.22; 0.05, 0.95), and mental health (OR 0.79; 0.63,0.99) reduced work loss.

Conclusion: Both men and women report impairments with work and leisure activities that improve over time but plateau. A small proportion of ERA patients stop work due to RA or report retiring early with sex differences between those that stop vs continue driven mostly by age, number of people living in the household, pain and mental health. Women that stop working due to RA are less likely than men to report returning to work. Interventions to optimize continued engagement in work may improve productivity outcomes for RA patients and their employers.

Supporting image 1

WPAI scores over the first five years of follow-up stratified by sex


Disclosures: C. Hitchon, Pfizer Canada, Astra-Zeneca Canada, Pfizer; M. Valois, None; o. schieir, None; L. Bessette, AbbVie/Abbott, Amgen, Bristol-Myers Squibb(BMS), Celgene, Eli Lilly, Janssen, Novartis, Pfizer, Sanofi-Genzyme, UCB, Gilead, Merck/MSD, Organon, Roche; G. Boire, AbbVie/Abbott, Bristol-Myers Squibb(BMS), Janssen, Eli Lilly, Merck/MSD, Novartis, Orimed Pharma, Pfizer, Samsung Bioepis, Teva, Viatris, Amgen, Celgene; S. Bartlett, Pfizer, Novartis, Merck/MSD, Janssen, AbbVie/Abbott, Organon; G. Hazlewood, None; E. Keystone, AbbVie/Abbott, Amgen, Gilead, Eli Lilly, Merck/MSD, Pfizer, Sanofi, Bristol-Myers Squibb(BMS), Celltrion, Myriad Autoimmune, F. Hoffmann-La Roche Inc, Genentech, Janssen, Sandoz, Samsung Bioepsis, AstraZeneca, Samsung Bioepsis; J. Pope, AbbVie/Abbott, Bristol-Myers Squibb(BMS), Eli Lilly, merk, Roche, Seattle Genetics, UCB, Actelion, Amgen, Bayer, Eicos Sciences, Emerald, Gilead, Janssen, Novartis, Pfizer, Sandoz, Sanofi, Boehringer Ingelheim; C. Thorne, AbbVie/Abbott, Amgen, Celgene, CaREBiodam, Centocor, Janssen, Eli Lilly, Novartis, Pfizer, Sanofi, Medexus/Medac, Merck; D. Tin, None; V. Bykerk, Amgen, Bristol-Myers Squibb(BMS), Genzyme, Brainstorm, Gilead, Regeneron, UCB, Pfizer, Sanofi, Aventis.

To cite this abstract in AMA style:

Hitchon C, Valois M, schieir o, Bessette L, Boire G, Bartlett S, Hazlewood G, Keystone E, Pope J, Thorne C, Tin D, Bykerk V. Sex Differences in Employment Outcomes in Patients with Recent Onset Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/sex-differences-in-employment-outcomes-in-patients-with-recent-onset-rheumatoid-arthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/sex-differences-in-employment-outcomes-in-patients-with-recent-onset-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology